People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. | — | Biotechnology | Series B | $110.4M | $136.3M | 2018 |
| Hastings Holding Corp. | — | Other | Series B | $40.6M | $263.6M | 2013 |
| Trillium Therapeutics Inc. | — | Pharmaceuticals | Series B | $20.0M | $679.2M | 2017 |
| JSI Holding Corp. | — | Other | Series B | $17.6M | $24.9M | 2012 |
| Sernova Corp. | — | Biotechnology | Pre-Seed | $573K | $2.0M | 2019 |
| Sernova Biotherapeutics Inc. | — | Biotechnology | Pre-Seed | $345K | $695K | 2025 |
JAMES PARSONS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside JAMES PARSONS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Rigby | 2 | 4 |
| James T. Parsons | 2 | 2 |
| Bernd Muehlenweg | 2 | 2 |
| Michael Moore | 1 | 12 |
| John Brooks | 1 | 8 |
| DAVID BURKE | 1 | 3 |
| Dan Negrea | 1 | 3 |
| MICHAEL RUBEL | 1 | 3 |
| Robert Kirkman | 1 | 3 |
| Rick Pauls | 1 | 3 |
| Thomas Reynolds | 1 | 2 |
| Scott Kellen | 1 | 2 |
| Todd Verdoorn | 1 | 2 |
| NED TRUSLOW | 1 | 2 |
| Frank A. Holler | 1 | 2 |
| Richard P. Kuntz | 1 | 2 |
| Richard Pilnik | 1 | 2 |
| ROBERT KOLLAR | 1 | 2 |
| Jeffrey A. Bacha | 1 | 2 |
| SEAN E. GILLICK | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.